Novo Nordisk trims forecast on US headwinds
This article was originally published in Scrip
Novo Nordisk has reported weaker than expected first quarter results. Sales grew by 7% in local currencies to DKK20.3bn, meaning the world's biggest insulin manufacturer failed to report quarterly double-digit sales growth for the first time in 12 years. The Danish company has now trimmed its forecast for full-year sales growth from 8-11% to 7-10%.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.